• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    7/31/23 2:54:35 PM ET
    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

     

    On Monday, 27 stocks hit new 52-week lows.

    Interesting Points From Today's 52-Week Lows:

    • The largest company by market cap to hit a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS).
    • Esports Entertainment (NASDAQ:GMBL) was the smallest company by market cap to set a new 52-week low.
    • Theratechnologies (NASDAQ:THTX)'s stock came under the most pressure, trading down 252.48% to reach a new 52-week low.
    • Artesian Resources (NASDAQ:ARTNA) shares bounced back the most, actually rising 0.04% after hiting a new 52-week low.

    The following stocks set new 52-week lows on Monday:

    • Apellis Pharmaceuticals (NASDAQ:APLS) shares moved down 18.14% on Monday to hit a new 52-week low of $25.48, drifting down 18.14%.
    • Impinj (NASDAQ:PI) shares hit a yearly low of $65.03. The stock was down 2.54% on the session.
    • Artesian Resources (NASDAQ:ARTNA) shares made a new 52-week low of $45.27 on Monday. The stock was down 0.04% for the day.
    • Vanda Pharma (NASDAQ:VNDA) shares hit a yearly low of $5.58. The stock was down 2.61% on the session.
    • Prelude Therapeutics (NASDAQ:PRLD) stock dropped to a yearly low on Monday of $3.92. Shares traded down 1.51%.
    • SWK Holdings (NASDAQ:SWKH) stock hit a yearly low of $15.87. The stock was up 0.38% for the day.
    • Silicom (NASDAQ:SILC) stock hit a yearly low of $29.00. The stock was down 25.43% for the day.
    • Complete Solaria (NASDAQ:CSLR) shares set a new 52-week low of $3.31. The stock traded down 7.95%.
    • Matinas BioPharma Hldgs (AMEX:MTNB) stock hit a new 52-week low of $0.32. The stock was down 8.33% on the session.
    • CEL-SCI (AMEX:CVM) shares set a new 52-week low of $1.51. The stock traded down 6.12%.
    • Dare Bioscience (NASDAQ:DARE) shares reached a new 52-week low of $0.73 on Monday morning, moving up 0.47%.
    • Delta Apparel (AMEX:DLA) shares set a new 52-week low of $8.36. The stock traded down 3.24%.
    • Theratechnologies (NASDAQ:THTX) shares set a new 52-week low of $1.74. The stock traded up 252.48%.
    • Purple Biotech (NASDAQ:PPBT) shares fell to $1.02 on Monday, setting a new 52-week low with a shift of down 4.5%.
    • Datasea (NASDAQ:DTSS) stock set a new 52-week low of $0.71 on Monday, moving down 3.97%.
    • Capstone Green Energy (NASDAQ:CGRN) shares set a new 52-week low of $0.92. The stock traded down 4.9%.
    • GRI Bio (NASDAQ:GRI) shares made a new 52-week low of $3.45 on Monday. The stock was up 2.59% for the day.
    • Pop Culture Gr (NASDAQ:CPOP) stock hit a new 52-week low of $0.39. The stock was down 3.15% on the session.
    • ABVC BioPharma (NASDAQ:ABVC) shares reached a new 52-week low of $2.46 on Monday morning, moving down 5.58%.
    • Biolase (NASDAQ:BIOL) shares hit a yearly low of $5.75. The stock was down 10.07% on the session.
    • Takung Art (AMEX:TKAT) stock achieved a new 52-week low on Monday morning, hitting $0.16 and moving down 14.68%.
    • Bone Biologics (NASDAQ:BBLG) stock set a new 52-week low of $1.24 on Monday, moving down 2.27%.
    • Eightco Holdings (NASDAQ:OCTO) shares made a new 52-week low of $1.30 on Monday. The stock was down 4.14% for the day.
    • Blue Star Foods (NASDAQ:BSFC) stock hit a yearly low of $0.85. The stock was down 13.73% for the day.
    • Esports Entertainment (NASDAQ:GMBL) shares set a new yearly low of $0.40 this morning. The stock was down 6.98% on the session.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $APLS
    $ARTNA
    $BBLG

    CompanyDatePrice TargetRatingAnalyst
    Impinj Inc.
    $PI
    11/7/2025$200.00Neutral
    UBS
    Apellis Pharmaceuticals Inc.
    $APLS
    11/6/2025Peer Perform
    Wolfe Research
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Apellis Pharmaceuticals Inc.
    $APLS
    10/15/2025$32.00Overweight
    Wells Fargo
    Impinj Inc.
    $PI
    10/8/2025$200.00Overweight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    9/26/2025$18.00Neutral → Sell
    Goldman
    Apellis Pharmaceuticals Inc.
    $APLS
    5/9/2025$23.00Buy → Neutral
    BofA Securities
    Apellis Pharmaceuticals Inc.
    $APLS
    5/9/2025$52.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    SEC Filings

    View All

    Impinj Inc. filed SEC Form 8-K: Leadership Update

    8-K - IMPINJ INC (0001114995) (Filer)

    12/22/25 4:10:25 PM ET
    $PI
    Industrial Machinery/Components
    Technology

    SEC Form PRE 14A filed by GRI Bio Inc.

    PRE 14A - GRI Bio, Inc. (0001824293) (Filer)

    12/19/25 8:48:54 AM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by GRI Bio Inc.

    SCHEDULE 13G - GRI Bio, Inc. (0001824293) (Subject)

    12/17/25 8:19:32 PM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Impinj with a new price target

    UBS initiated coverage of Impinj with a rating of Neutral and set a new price target of $200.00

    11/7/25 8:30:20 AM ET
    $PI
    Industrial Machinery/Components
    Technology

    Wolfe Research initiated coverage on Apellis Pharmaceuticals

    Wolfe Research initiated coverage of Apellis Pharmaceuticals with a rating of Peer Perform

    11/6/25 8:48:03 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Vanda Pharma with a new price target

    B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00

    11/5/25 7:30:12 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Taylor Dian C sold $71,101 worth of Class A Non-voting Common Stock (2,224 units at $31.97) (SEC Form 4)

    4 - ARTESIAN RESOURCES CORP (0000863110) (Issuer)

    12/22/25 12:24:14 PM ET
    $ARTNA
    Water Supply
    Utilities

    Director Taylor Dian C sold $70,561 worth of Class A Non-voting Common Stock (2,224 units at $31.73) (SEC Form 4)

    4 - ARTESIAN RESOURCES CORP (0000863110) (Issuer)

    12/22/25 10:46:38 AM ET
    $ARTNA
    Water Supply
    Utilities

    General Counsel Watson David O. sold $122,450 worth of shares (5,000 units at $24.49), decreasing direct ownership by 5% to 103,730 units (SEC Form 4)

    4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    12/18/25 4:06:50 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kersten Geert R bought $49,998 worth of shares (8,389 units at $5.96), increasing direct ownership by 11% to 81,794 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    12/5/25 8:48:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO O'Donnell Kevin J bought $250,000 worth of shares (171,233 units at $1.46) and was granted 400,000 shares, increasing direct ownership by 1,987% to 599,985 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/11/25 8:07:01 AM ET
    $OCTO

    Director Jennings Frank D bought $200,000 worth of shares (136,986 units at $1.46), increasing direct ownership by 796% to 154,189 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/10/25 3:59:46 PM ET
    $OCTO

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

    VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology breakthroughs[1]. This momentum is already materializing, with five major oncology approvals secured in November across multiple cancer indications, demonstrating regulators' willingness to green-light promising therapies when supported by compelling clinical data[2]. Against this backdrop of regulatory evolution, several clinical-stage biotechs are advancing toward definitive registration studies and commercial readiness, po

    12/16/25 12:18:00 PM ET
    $CNTX
    $IMNM
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

    WASHINGTON, Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36RA regulator commonly seen in GPP patients due to IL36RN gene mutations. The BLA is supported by positive results from the global Phase 3 GEMINI-1 and GEMINI-2 studies, wher

    12/15/25 7:00:00 AM ET
    $ANAB
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GRI Bio Announces Closing of $8.0 Million Public Offering

    LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 10,666,667 shares of its common stock (or common stock equivalents in lieu thereof), Series F warrants to purchase up to 10,666,667 shares of common stock (the "Series F Warrants"), at a combined public offering price of $0.75 per share (or per common stock equivalent in lieu thereof) and accompanying Series F Warrant. The Series

    12/12/25 4:05:00 PM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Leadership Updates

    Live Leadership Updates

    View All

    SunPower Closes $37.5M Ambia Solar Acquisition

    OREM, Utah, Nov. 24, 2025 (GLOBE NEWSWIRE) -- SunPower Inc. (herein "SunPower," the "Company," or Nasdaq: "SPWR") a solar technology, services, and installation company, today announced that it has closed its $37.5 million strategic acquisition of Ambia Solar ("Ambia") to create the No. 5 U.S. residential solar company, based on Ohm Analytics rankings. SunPower CEO T.J. Rodgers said, "Due to our quick closing of the acquisition, we are raising our Q4'25 quarterly revenue estimate to $88 million. We still expect record operating income in Q4'25 and at least $2.0 million in operating income in Q1'26, the winter solar "down" quarter. In addition, and equally important, the acquisition brings

    11/24/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    SunPower Signs LOI to Acquire Ambia Solar

    OREM, Utah, Nov. 11, 2025 (GLOBE NEWSWIRE) -- SunPower (herein "SunPower," the "Company" or Nasdaq: "SPWR") – a solar technology, services, and installation company – today announced that it has agreed to acquire Ambia Solar ("Ambia"), based in Lindon, Utah, just 1.7 miles from SunPower's HQ. Ambia is the No. 19 U.S. solar company by installed megawatts as reported by Ohm Analytics. The companies have signed a non-binding LOI for $37.5 million in equity. The transaction will close this quarter (Q4'25), subject to customary closing conditions. (The verb "will" in this press release should be interpreted as "will pursue the result stated in a definitive agreement scheduled for Q4'25 and act

    11/11/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    SunPower Executes Major Sales Force Expansion Following Sunder Merger

    OREM, Utah, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SunPower Inc. (NASDAQ:SPWR) a solar technology, services, and installation company, this morning announced the successful integration of the Sunder salesforce into the company — as SunPower continues to execute on plan and expects to achieve record revenue of $83.3 million and record operating income of $3.5 million in Q4 2025. Eric Nielsen, SunPower's EVP of Sales said, "I am happy to report the integration of Sunder's salesforce into SunPower has been seamless and as a result, has enabled our team to continue to execute on plan without missing a beat. In addition, this deal has been well received across the industry — evidenced by the fact t

    10/30/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Blue Star Foods Corp.

    SC 13G/A - Blue Star Foods Corp. (0001730773) (Subject)

    11/14/24 7:34:10 PM ET
    $BSFC

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product RevenuePositive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting as well as Non-Hormonal ContraceptionFour Commercially Available Solutions for Women Expected Over the Next Two Years In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of DARE to RESTORE™ Vaginal Probiotics in the Consumer Health Market Targeted to follow DARE to PLAY Sildenafil Cream availability and DARE to RECLAIM™ Monthly Hormone Therapy via 503B Compounding Pathway Targeted for Ea

    11/13/25 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CALR-targeted degrader antibody conjugate (DAC) program were both accepted for oral presentations at the American Society of Hematology (ASH) 67th Annual Meeting in December Current cash runway into 2027 based on preliminary estimates Company to host investor conference call and webcast on Wednesday, November 12, 2025 at 8:00 AM EST WILMINGTON, Del., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Prelude T

    11/12/25 7:01:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

    SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2025, to review its financial results for the quarter ended September 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 5794075. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website a

    11/6/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care